Bortezomib Completed Phase 2 Trials for Recurrent Melanoma / Stage IV Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00024011PS-341 in Treating Patients With Metastatic Malignant Melanoma